Antipsychotic Medication and Risk of Metabolic Disorders in People With Schizophrenia: A Longitudinal Study Using the UK Clinical Practice Research Datalink
暂无分享,去创建一个
D. Kessler | E. Eyles | S. Sullivan | M. T. Redaniel | Simon J. C. Davies | R. Margelyte | H. Edwards | P. Moran | B. Bolea-Alamañac
[1] S. Davies,et al. Visualizing classification of drugs used in psychotic disorders: A ‘subway map’ representing mechanisms, established classes and informal categories , 2022, Journal of psychopharmacology.
[2] S. Cooper,et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology , 2019, Journal of psychopharmacology.
[3] M. Scarselli,et al. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences , 2018, Pharmacology & therapeutics.
[4] L. Rojo,et al. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. , 2015, Pharmacological research.
[5] K. Bhaskaran,et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.
[6] C. Correll,et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder , 2015, World psychiatry : official journal of the World Psychiatric Association.
[7] Maudsley Nhs Trust,et al. The Maudsley Prescribing Guidelines in Psychiatry , 2015 .
[8] P. Ho,et al. Estimating the effects of time‐varying exposures in observational studies using Cox models with stabilized weights adjustment , 2014, Pharmacoepidemiology and drug safety.
[9] P. Mortensen,et al. Excess early mortality in schizophrenia. , 2014, Annual review of clinical psychology.
[10] S. Stahl. Antipsychotic polypharmacy: never say never, but never say always , 2012, Acta psychiatrica Scandinavica.
[11] T. Wetterling,et al. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs , 2011, International clinical psychopharmacology.
[12] J. Langan,et al. Antipsychotic polypharmacy: review of mechanisms, mortality and management , 2010 .
[13] M. Tancer,et al. The story of antipsychotics: Past and present , 2009, Indian journal of psychiatry.
[14] Mondher Toumi,et al. Predictors of employment status change over 2 years in people with schizophrenia living in Europe , 2009, Epidemiology and Psychiatric Sciences.
[15] M. Kenward,et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls , 2009, BMJ : British Medical Journal.
[16] C. Correll,et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. , 2009, Schizophrenia bulletin.
[17] Henry A. Nasrallah,et al. Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology , 2008, Schizophrenia Research.
[18] Alexander L. Miller,et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. , 2007, The Journal of clinical psychiatry.
[19] L. Moore,et al. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards – a cluster randomized controlled trial , 2007, Psychological Medicine.
[20] D. Nutt,et al. Panic and hypertension: brothers in arms through 5-HT? , 2007, Journal of psychopharmacology.
[21] C. Correll,et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? , 2007, Schizophrenia Research.
[22] Peter B. Jones,et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.
[23] Patrick Royston,et al. Multiple Imputation of Missing Values: Update of Ice , 2005 .
[24] C. Correll,et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics , 2005, BMC psychiatry.
[25] R. Holt,et al. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia , 2004, British Journal of Psychiatry.
[26] P. Lelliott,et al. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK , 2002 .
[27] N. Keltner,et al. Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? , 2002, Perspectives in psychiatric care.
[28] Philip Seeman,et al. Atypical Antipsychotics: Mechanism of Action , 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[29] E. Laska,et al. Recovery from psychotic illness: A 15- and 25-year international follow-up study , 2001, British Journal of Psychiatry.
[30] W. Shen. A history of antipsychotic drug development. , 1999, Comprehensive psychiatry.
[31] World federation of societies of biological psychiatry , 1990, Biological Psychiatry.